|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effects of Surgical Laparoscopic Experience on the Short-term Postoperative Outcome of Rectal Cancer: Results of a High Volume Single Center Institution显示文摘 | Emre Balik Oktar Asoglu Sezer Saglam Sumer Yamaner Ali Akyuz Yilmaz Buyukuncu Mine Gulluoglu Turker Bulut Dursun Bugra | 2010 | Surgical Laparoscopy Endoscopy & Percutaneous Techniques2010，，2： | 1 |
| 2 | Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C显示文摘 | Ahmet Uyanikoglu Filiz Akyuz Bulent Baran Binnur Pinarbasi Simsek Fatih Ermis Kadir Demir Mine Gulluoglu Selim Badur Sabahattin Kaymakoglu | 2013 | Clinics and Research in Hepatology and Gastroenterology2013，，： | 1 |
| 3 | Association of APE1 and hOGG1 polymorphisms with colorectal cancer risk in a Turkish population显示文摘 | Emel Canbay Bedia Cakmakoglu Umit Zeybek Seyma Sozen Canan Cacina Mine Gulluoglu Emre Balik Turker Bulut Sumer Yamaner Dursun Bugra | 2011 | Current Medical Research & Opinion2011，，7： | 1 |
| 4 | Laparoscopic Surgery for Rectal Cancer: Outcomes in 513 Patients显示文摘 | Oktar Asoglu Emre Balik Enver Kunduz Sumer Yamaner Ali Akyuz Mine Gulluoglu Yersu Kapran Dursun Bugra | 2013 | World Journal of Surgery2013，，： | 1 |
| 5 | Nodular Lymphoid Hyperplasia of Duodenum Caused by Giardiasis显示文摘 | Bulent Baran Mine Gulluoglu Filiz Akyuz | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 1 |
| 6 | Congenital Portal Vein Aneurysm Associated with Peliosis Hepatis and Intestinal Lymphangiectasia显示文摘 | Zeynel Mungan Binnur Pinarbasi Baris Bakir Mine Gulluoglu Bulent Baran Filiz Akyuz Kadir Demir Sabahattin Kaymakoglu Juan G. Abraldes | 2010 | Gastroenterology Research and Practice2010，，： | 1 |
| 7 | Current state and clinical outcome in Turkish patients with hepatocellular carcinoma显示文摘AIM To investigate clinical, etiological, and prognostic features in patients with hepatocellular carcinoma.METHODS Patients with hepatocellular carcinoma who were followed-up from 2001 to 2011 were included in the study. The diagnosis was established by histopathological and/or radiological criteria. We retrospectively reviewed clinical and laboratory data, etiology of primary liver disease, imaging characteristics and treatments. ChildPugh and Barcelona Clinic Liver Cancer stage was determined at initial diagnosis. Kaplan-Meier survival analysis was done to find out treatment effect on survival. Risk factors for vascular invasion and overall survival were investigated by multivariate Cox regression analyses. RESULTS Five hundred and forty-five patients with hepatocellular carcinoma were included in the study. Viral hepatitis was prevalent and 68 patients either had normal liver or were non-cirrhotic. Overall median survival was 16(13-19) mo. Presence of extrahepatic metastasis was associated with larger tumor size(OR = 3.19, 95%CI: 1.14-10.6). Independent predictor variables of vascular invasion were AFP(OR = 2.95, 95%CI: 1.38-6.31), total tumor diameter(OR = 3.14, 95%CI: 1.01-9.77), and hepatitis B infection( OR = 5.37, 95 % CI : 1.23-23.39). Liver functional reserve, tumor size/extension, AFP level and primary treatment modality were independent predictors of overall survival. Transarterial chemoembolization(HR = 0.38, 95%CI: 0.28-0.51) and radioembolization(HR = 0.36, 95%CI: 0.18-0.74) provided a comparable survival benefit in the real life setting. Surgical treatments as resection and transplantation were found to be associated with the best survival compared with loco-regional treatments(log-rank, P < 0.001).CONCLUSION Baseline liver function, oncologic features including AFP level and primary treatment modality determines overall survival in patients with hepatocellular carcinoma. | Omer Ekinci Bulent Baran Asli Cifcibasi Ormeci Ozlem Mutluay Soyer Suut Gokturk Sami Evirgen Arzu Poyanli Mine Gulluoglu Filiz Akyuz Cetin Karaca Kadir Demir Fatih Besisik Sabahattin Kaymakoglu | 2018 | World Journal of Hepatology2018，10，1： | 0 |
| 8 | Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+rectal cancer:Istanbul R-02 phase II randomized study显示文摘Radiation therapy(RT)is typically applied using one of two standard approaches for preoperative treatment of resectable locally advanced rectal cancer(LARC):short-course RT(SC-RT)alone or long-course RT(LC-RT)with concurrent fluorouracil(5-FU)chemotherapy.The Phase II single-arm KROG 11-02 study using intermediate-course(IC)(33 Gy(Gray)/10 fr(fraction)with concurrent capecitabine)preoperative chemoradiotherapy(CRT)demonstrated a pathologically complete response rate and a sphincter-sparing rate that were close to those of LC-CRT.The current trial aim to compare the pathological/oncological outcomes,toxicity,and quality of life results of LC-CRT and IC-CRT in cases of LARC.The prescribed dose was 33 Gy/10 fr for the IC-CRT group and 50.4 Gy/28 fr for the LC-CRT group.Concurrent chronomodulated capecitabine(Brunch regimen)1650 mg/m2/daily chemotherapy treatment was applied in both groups.The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer Module(EORTC QLQ-CR29)was administered at baseline and at three and six months after CRT.A total of 60 patients with LARC randomized to receive IC-CRT(n=30)or LC-CRT(n=30)were included in this phase II randomized trial.No significant difference was noted between groups in terms of pathological outcomes,including pathological response rates(ypT0N0-complete response:23.3%vs.16.7%,respectively,and ypT0-2N0-downstaging:50%for each;p=0.809)and Dworak score-based pathological tumor regression grade(Grade 4-complete response:23.3 vs.16.7%,p=0.839).The 5-year overall survival(73.3 vs.86.7%,p=0.173)rate was also similar.The acute radiation dermatitis(p<0.001)and any hematological toxicity(p=0.004)rates were significantly higher in the LC-CRT group,while no significant difference was noted between treatment groups in terms of baseline,third month,and sixth month EORTC QLQ-CR29 scores. | SUKRAN SENYUREK SEZER SAGLAM ESRA KAYTAN SAGLAM HAKAN YANAR KAAN GOK DIDEM TASTEKIN CANAN KOKSAL AKBAS NERGIZ DAGOGLU SAKIN GULBIZ DAGOGLU KARTAL EMRE BALIK METIN KESKIN YASEMIN SANLI MINE GULLUOGLU ZULEYHA AKGUN | 2023 | Oncology Research2023，31，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员